Merck and GlaxoSmithKline Collaborate on Pazopanib - - BioPharm International

ADVERTISEMENT

Merck and GlaxoSmithKline Collaborate on Pazopanib



Merck & Co. announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s (GSK) orally administered kinase inhibitor, pazopanib, for the treatment of advanced renal-cell carcinoma.

Merck and GSK entered a collaboration to study MK-3475 with pazopanib and other agents in the GSK portfolio. This Phase I and Phase II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal-cell carcinoma.

Source: Merck & Co.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here